Mirum Pharmaceuticals (NASDAQ:MIRM) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Mirum Pharmaceuticals (NASDAQ:MIRM) from a sell rating to a hold rating in a report released on Saturday.

A number of other equities analysts also recently commented on MIRM. Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Robert W. Baird set a $123.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, August 6th. UBS Group set a $137.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday. CLSA set a $146.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Finally, Wolfe Research assumed coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $137.31.

Mirum Pharmaceuticals Stock Down 2.3%

Shares of NASDAQ:MIRM opened at $97.46 on Friday. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The business has a fifty day moving average of $110.63 and a two-hundred day moving average of $101.79. The stock has a market cap of $6.33 billion, a P/E ratio of -6.70 and a beta of 0.52. Mirum Pharmaceuticals has a 52-week low of $63.23 and a 52-week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The company had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm’s revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.12) EPS. On average, research analysts expect that Mirum Pharmaceuticals will post -1.31 earnings per share for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the sale, the senior vice president directly owned 1,274 shares of the company’s stock, valued at approximately $127,400. The trade was a 96.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Eric Bjerkholt sold 6,001 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the sale, the chief financial officer owned 36,355 shares in the company, valued at $3,631,864.50. This represents a 14.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 133,156 shares of company stock worth $13,763,562 over the last ninety days. Company insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cullen Frost Bankers Inc. purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $32,000. CIBC Private Wealth Group LLC purchased a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $32,000. Quantbot Technologies LP acquired a new stake in Mirum Pharmaceuticals during the 3rd quarter worth approximately $33,000. Finally, Comerica Bank boosted its position in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.